our Premium Content: News alerts, weekly reports and conference planners

GENE:

CXCL14 (C-X-C Motif Chemokine Ligand 14)

News alerts, weekly reports and conference planners

Integrative analysis of polyamine-associated genes reveals a prognostic and immunological signature in esophageal squamous cell carcinoma. (PubMed, Discov Oncol)

Drug sensitivity analysis based on oncoPredict revealed compounds with differential efficacy between risk groups, and the model also predicted response to PD-1 blockade in an external immunotherapy cohort. In summary, polyamine metabolism is closely linked to the immune microenvironment and prognosis of ESCA, providing a potential biomarker for patient stratification and treatment optimization.

5 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SQSTM1 (Sequestosome 1) • LYPD3 (LY6/PLAUR Domain Containing 3) • KRT14 (Keratin 14) • MUC5B (Mucin 5B, Oligomeric Mucus/Gel-Forming) • RUNX3 (RUNX Family Transcription Factor 3) • CXCL14 (C-X-C Motif Chemokine Ligand 14)

10d

COPD reshapes the tumor microenvironment of NSCLC and enhances anti-PD-1 therapy response. (PubMed, Med)

Our findings define a mechanistic link between COPD comorbidity and enhanced PD-1 blockade efficacy. The presence of this tumor-macrophage axis in patients with NSCLC with favorable immunotherapy outcomes highlights its translational potential as both a predictive biomarker and a therapeutic target to improve checkpoint blockade responsiveness.

10 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL14 (C-X-C Motif Chemokine Ligand 14)

25d

NK cells in HPV-related tumorigenesis: mechanisms and clinical applications. (PubMed, Front Cell Infect Microbiol)

Additionally, it discusses emerging therapeutic strategies to enhance NK cell activation, such as pharmacological agents (e.g., γ-PGA, α-GalCer), innate immune agonists (e.g., STING, RIG-I), genetic engineering (e.g., CAR-NK, iPSC-NK cells), and combination therapies with immune checkpoint inhibitors or monoclonal antibodies (e.g., cetuximab)...Despite challenges like immunosuppressive tumor microenvironments and limited NK cell persistence, advancements in genetic engineering and nanoparticle delivery systems offer promising solutions. Future research should focus on integrating mechanistic insights with clinical trial design to optimize NK cell-based therapies for HPV-associated malignancies.

25 days ago

Review • Journal • IO biomarker

TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • STING (stimulator of interferon response cGAMP interactor 1) • KLRG1 (Killer Cell Lectin Like Receptor G1) • CXCL14 (C-X-C Motif Chemokine Ligand 14)

Erbitux (cetuximab)

AF6 knockout-induced upregulation of bile acid production promotes CXCL14-mediated antitumor immunity in HCC: Effect of the BA/Butyrate/CXCL14 axis in HCC. (PubMed, J Hepatol)

AF6 modulates primary BA synthesis, driving gut microbiota-dependent butyrate production and Cxcl14-mediated immune remodeling in HCC. This axis highlights a novel mechanism linking BA metabolism, gut microbiota, and immune regulation, offering potential therapeutic targets for liver cancer treatment.

1 month ago

Journal

CD8 (cluster of differentiation 8) • CXCL14 (C-X-C Motif Chemokine Ligand 14)

CXCL14 Promotes Ovarian Cancer Progression and Autophagy Through the IKBKE/NF-κB Pathway. (PubMed, J Gene Med)

In vivo, CXCL14 overexpression markedly enhances ovarian tumor growth, accompanied by increased levels of IKBKE and phosphorylated p65. These findings elucidate a novel regulatory axis, CXCL14/IKBKE/NF-κB, in ovarian cancer progression, highlighting CXCL14 as a potential therapeutic target for ovarian cancer treatment.

1 month ago

Journal

IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon) • NFKBIA (NFKB Inhibitor Alpha 2) • CXCL14 (C-X-C Motif Chemokine Ligand 14)

2ms

Differentially Expressed Genes Associated with the Development of Cervical Cancer. (PubMed, Int J Mol Sci)

The publicly available microarray datasets, including GSE39001, GSE9750, GSE7803, GSE6791, GSE63514, and GSE52903 in combination with bioinformatics database predictions, were used to identify differential expression genes, potential biomarkers, and therapeutic targets for cervical cancer; additionally, we undertook bioinformatic analysis to determine gene ontology and possible miRNA targets related to our DEGs...Interestingly, hub proteins KIF4A, NUSAP1, BUB1B, CEP55, DLGAP5, NCAPG, CDK1, MELK, KIF11, and KIF20A were found to be potentially regulated by several miRNAs, including miR-107, miR-124-3p, miR-147a, miR-16-5p, miR-34a-5p, miR-34c-5p, miR-126-3p, miR-10b-5p, miR-23b-3p, miR-200b-3p, miR-138-5p, miR-203a-3p, miR-214-3p, and let-7b-5p. The relationship between these genes highlights their potential as candidate biomarkers for further research in treatment, diagnosis, and prognosis.

2 months ago

Journal

TP53 (Tumor protein P53) • TOP2A (DNA topoisomerase 2-alpha) • RAD51 (RAD51 Homolog A) • MIR200B (MicroRNA 200b) • MIR34A (MicroRNA 34a-5p) • RAD51AP1 (RAD51 Associated Protein 1) • NUSAP1 (Nucleolar and Spindle Associated Protein 1) • ELF3 (E74 Like ETS Transcription Factor 3) • FOXM1 (Forkhead Box M1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • MIR126 (MicroRNA 126) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • NCAPG (Non-SMC Condensin I Complex Subunit G) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CEP55 (Centrosomal Protein 55) • CXCL14 (C-X-C Motif Chemokine Ligand 14) • E2F1 (E2F transcription factor 1) • KIF20A (Kinesin Family Member 20A) • KIF4A (Kinesin Family Member 4A) • MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • MIR10B (MicroRNA 10b) • MIR138 (MicroRNA 138) • MIR203A (MicroRNA 203a) • MIR214 (MicroRNA 214) • MIRLET7B (MicroRNA Let-7b) • RELA (RELA Proto-Oncogene) • RFC4 (Replication Factor C Subunit 4) • MIR124-3 (MicroRNA 124-3)

2ms

Unraveling risk factors and transcriptomic signatures in liver cancer progression and mortality through machine learning and bioinformatics. (PubMed, Brief Funct Genomics)

Additionally, an independent survival analysis using the full TCGA transcriptomic dataset identified 76 significant genes, with 18 overlapping the risk-associated gene set, reinforcing their prognostic value. Overall, this study demonstrates the potential of an integrative computational approach to uncover meaningful biomarkers and pathways in LC, offering valuable insights for future clinical and therapeutic strategies.

2 months ago

Journal

CXCL14 (C-X-C Motif Chemokine Ligand 14)

3ms

Expression of Tetraspanin 4 Relative to Therapy-induced Senescence Markers in Breast Cancer in Response to Neoadjuvant Chemotherapy. (PubMed, J Histochem Cytochem)

NAG2 was upregulated in 54/68 patients post-NAC (p<0.00001) and its expression correlated positively with senescence-associated genes. An association between TSPAN4 and TIS post-NAC was identified.

3 months ago

Journal

MMP2 (Matrix metallopeptidase 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • IGFBP7 (Insulin Like Growth Factor Binding Protein 7) • CXCL14 (C-X-C Motif Chemokine Ligand 14)

4ms

Genetic and pharmacokinetic factors associated with imatinib-induced toxicities in gastrointestinal stromal tumors. (PubMed, Pharmacogenomics J)

These findings identify novel pharmacogenetic markers for imatinib-induced toxicities, supporting the potential of personalized treatment strategies through genetic testing and therapeutic drug monitoring. Further validation in larger cohorts is needed.

4 months ago

PK/PD data • Retrospective data • Journal

EGFR (Epidermal growth factor receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • FLT1 (Fms-related tyrosine kinase 1) • MAPK1 (Mitogen-activated protein kinase 1) • CXCL14 (C-X-C Motif Chemokine Ligand 14)

imatinib

4ms

Tubal occlusion in patients with hydrosalpinx modifies the uterine environment and improves in vitro fertilization outcomes within 7 months. (PubMed, J Ovarian Res)

This study demonstrates that oocyte retrieval within 7 months after tubal occlusion is optimal for patients with hydrosalpinx, potentially due to CXCL14-mediated modulation of the endometrial immune microenvironment.

4 months ago

Preclinical • Retrospective data • Journal

CD163 (CD163 Molecule) • CXCL14 (C-X-C Motif Chemokine Ligand 14)

5ms

Construction and evaluation of a prognostic model for breast cancer based on aging related genes. (PubMed, Sci Rep)

Furthermore, CXCL14 further suppressed tumor occurrence and development by activating CD8+ T cell-mediated immune mechanisms. In this study, the aging-related genes JCHAIN, KRT15, and CXCL14 were identified as key biomarkers for predicting the prognosis of BRCA.

5 months ago

Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CXCL14 (C-X-C Motif Chemokine Ligand 14)

5ms

Characterization of cancer-related fibroblasts in bladder cancer and construction of CAFs-based bladder cancer classification: insights from single-cell and multi-omics analysis. (PubMed, Front Immunol)

C1 is mainly enriched in metabolism-related pathways, and C2 is mainly enriched in the activation of genome instability pathways, accompanied by more frequent mutations and higher Atezolizumab response...This study identified a promising platform for understanding heterogeneity of CAFs-based BLCA subtypes, providing novel insights into the intricate molecular mechanisms of BLCA. Potential target genes for each subtype provide a basis for diagnosis and screening of BLCA patients.

5 months ago

Journal • PD(L)-1 Biomarker

CD74 (CD74 Molecule) • ACTA2 (Actin Alpha 2 Smooth Muscle) • CCL21 (C-C Motif Chemokine Ligand 21) • CXCL14 (C-X-C Motif Chemokine Ligand 14) • PSCA (Prostate Stem Cell Antigen 2) • STMN1 (Stathmin 1)

Tecentriq (atezolizumab)